Skip to main content
Top
Published in: Clinical Rheumatology 5/2016

01-05-2016 | Case Based Review

Lucio’s phenomenon: report of five cases

Authors: Pablo Finucci Curi, Julieta Solis Villaroel, Nora Migliore, Adriana Albertengo, María Laura Aquino, Federico Ceccato, Sergio Paira

Published in: Clinical Rheumatology | Issue 5/2016

Login to get access

Abstract

The different clinical forms of leprosy are mainly related to the variety of immunological responses to the infection. Several forms of lepromatous leprosy are recognized, including macular, nodular, and diffuse. Lucio’s phenomenon is a rare but distinctive skin eruption seen in patients with diffuse lepromatous leprosy. The diffuse lesions of Lucio’s phenomenon have a predilection for the extremities, can include nodules, and heal with atrophic stellate scars; histologically, a necrotizing vasculitis accompanied by a nonspecific inflammatory reaction may be seen. Because of its rarity and similarity with some manifestations of the rheumatic disease and other causes of vasculitis, Lucio’s phenomenon may not be easily recognized, especially in non-endemic countries, which leads to confusing diagnosis and loss of time for treatment. We report five patients with vasculitis caused by Lucio’s phenomenon.
Literature
1.
go back to reference Organización Mundial de la Salud. Estadísticas sanitarias mundiales 2011, pag 18 Organización Mundial de la Salud. Estadísticas sanitarias mundiales 2011, pag 18
2.
go back to reference World Health Organization. Leprosy updates 2011. Weekly Epidemiological Record September 2011, vol. 86, n 36 (pp 389–400) World Health Organization. Leprosy updates 2011. Weekly Epidemiological Record September 2011, vol. 86, n 36 (pp 389–400)
3.
go back to reference Cuevas J, Rodríguez-Peralto JL, Carrillo R, Contreras F (2007) Erythema nodosum leprosum: reactional leprosy. Semin Cutan Med Surg 26:126–130CrossRefPubMed Cuevas J, Rodríguez-Peralto JL, Carrillo R, Contreras F (2007) Erythema nodosum leprosum: reactional leprosy. Semin Cutan Med Surg 26:126–130CrossRefPubMed
4.
go back to reference Pernambuco JC, Cossermelli-Messina W (1993) Rheumatic manifestations of leprosy: clinical aspects. J Rheumatol 20:897–899PubMed Pernambuco JC, Cossermelli-Messina W (1993) Rheumatic manifestations of leprosy: clinical aspects. J Rheumatol 20:897–899PubMed
5.
go back to reference Roverano S, Paira S, Somma F (2000) Lucio’s phenomenon: report of two cases and review of the literature. J Clin Rheumatol 6:210–213CrossRefPubMed Roverano S, Paira S, Somma F (2000) Lucio’s phenomenon: report of two cases and review of the literature. J Clin Rheumatol 6:210–213CrossRefPubMed
6.
7.
go back to reference Magaña M, Fernández-Díez J, Magaña ML (2008) Lucio’s phenomenon is a necrotizing panvasculitis: mostly a medium-sized granulomatous arteritis. Am J Dermatopathol 30:555–560CrossRefPubMed Magaña M, Fernández-Díez J, Magaña ML (2008) Lucio’s phenomenon is a necrotizing panvasculitis: mostly a medium-sized granulomatous arteritis. Am J Dermatopathol 30:555–560CrossRefPubMed
8.
go back to reference Vargas OF (2007) Diffuse leprosy of Lucio and Latapí: a histologic study. Lepr Rev 78:248–260 Vargas OF (2007) Diffuse leprosy of Lucio and Latapí: a histologic study. Lepr Rev 78:248–260
9.
go back to reference Rea TH, Levan NE (1978) Lucio’s phenomenon and diffuse nonnodular lepromatous leprosy. Arch Dermatol 114:1023–1028CrossRefPubMed Rea TH, Levan NE (1978) Lucio’s phenomenon and diffuse nonnodular lepromatous leprosy. Arch Dermatol 114:1023–1028CrossRefPubMed
11.
go back to reference Kaur C, Thami GP, Mohan H (2005) Lucio phenomenon and Lucio leprosy. Clin Exp Dermatol 30:525–527CrossRefPubMed Kaur C, Thami GP, Mohan H (2005) Lucio phenomenon and Lucio leprosy. Clin Exp Dermatol 30:525–527CrossRefPubMed
12.
go back to reference Quismorio FP Jr, Rea T, Chandor S, Levan N, Friou GJ (1978) Lucio’s phenomenon: an immune complex deposition syndrome in lepromatous leprosy. Clin Immunol Immunopathol 9:184–193CrossRefPubMed Quismorio FP Jr, Rea T, Chandor S, Levan N, Friou GJ (1978) Lucio’s phenomenon: an immune complex deposition syndrome in lepromatous leprosy. Clin Immunol Immunopathol 9:184–193CrossRefPubMed
13.
go back to reference Moschella SL (1967) The lepra reaction with necrotizing skin lesions: a report of six cases. Arch Dermatol 95:565–575CrossRefPubMed Moschella SL (1967) The lepra reaction with necrotizing skin lesions: a report of six cases. Arch Dermatol 95:565–575CrossRefPubMed
14.
go back to reference Donner R, Shively J (1967) The Lucio’s phenomenon in diffuse leprosy. Ann Intern Med 67:831–836CrossRefPubMed Donner R, Shively J (1967) The Lucio’s phenomenon in diffuse leprosy. Ann Intern Med 67:831–836CrossRefPubMed
15.
go back to reference Chavez-Legaspi M, Gomez-Vazquez A, García-De La Torre I (1985) Study of rheumatic manifestations and serologic abnormalities in patients with lepromatous leprosy. J Rheumatol 12:738–741PubMed Chavez-Legaspi M, Gomez-Vazquez A, García-De La Torre I (1985) Study of rheumatic manifestations and serologic abnormalities in patients with lepromatous leprosy. J Rheumatol 12:738–741PubMed
16.
go back to reference Pradhan V, Badakere SS, Shankar KU (2004) Increased incidence of cytoplasmic ANCA (cANCA) and other auto antibodies in leprosy patients from western India. Lepr Rev 75:50–56PubMed Pradhan V, Badakere SS, Shankar KU (2004) Increased incidence of cytoplasmic ANCA (cANCA) and other auto antibodies in leprosy patients from western India. Lepr Rev 75:50–56PubMed
17.
go back to reference Zavala-Cerna MG, Fafutis-Morris M, Guillen-Vargas C et al (2012) Anti-cyclic citrullinated peptide antibodies and rheumatoid factor sera titers in leprosy patients from Mexico. Rheumatol Int 32:3531–3536CrossRefPubMed Zavala-Cerna MG, Fafutis-Morris M, Guillen-Vargas C et al (2012) Anti-cyclic citrullinated peptide antibodies and rheumatoid factor sera titers in leprosy patients from Mexico. Rheumatol Int 32:3531–3536CrossRefPubMed
18.
go back to reference de Larrañaga GF, Forastiero RR, Martinuzzo ME et al (2000) High prevalence of antiphospholipid antibodies in leprosy: evaluation of antigen reactivity. Lupus 9:594–600CrossRefPubMed de Larrañaga GF, Forastiero RR, Martinuzzo ME et al (2000) High prevalence of antiphospholipid antibodies in leprosy: evaluation of antigen reactivity. Lupus 9:594–600CrossRefPubMed
19.
go back to reference Loizou S, Singh S, Wypkema E, Asherson RA (2003) Anticardiolipin, anti-beta(2)-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease. Ann Rheum Dis 62:1106–1111CrossRefPubMedPubMedCentral Loizou S, Singh S, Wypkema E, Asherson RA (2003) Anticardiolipin, anti-beta(2)-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease. Ann Rheum Dis 62:1106–1111CrossRefPubMedPubMedCentral
20.
go back to reference Gelber R (1995) (Hansen’s disease) In: Mandell G, Bennett J, Dolin R, editors. Principles and Practice of Infectous Diseases. 4th ed. Vol 2. New York: Churchill-Livingston; P 2243–50 Gelber R (1995) (Hansen’s disease) In: Mandell G, Bennett J, Dolin R, editors. Principles and Practice of Infectous Diseases. 4th ed. Vol 2. New York: Churchill-Livingston; P 2243–50
Metadata
Title
Lucio’s phenomenon: report of five cases
Authors
Pablo Finucci Curi
Julieta Solis Villaroel
Nora Migliore
Adriana Albertengo
María Laura Aquino
Federico Ceccato
Sergio Paira
Publication date
01-05-2016
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 5/2016
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-014-2683-2

Other articles of this Issue 5/2016

Clinical Rheumatology 5/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine